[ad_1]
More than three decades after the identification of the human immunodeficiency virus (HIV), scientists are still working on the development of a preventative vaccine that could finally end the # An epidemic for which there are nearly two million new infections every year. 19659002] In a new study, published July 6 in The Lancet, a team of researchers led by Dan Beth Barouch, MD, Ph.D., Beth Israel Deaconess Medical Center, director of the Center for Virology and Vaccine Research in collaboration with Janssen Vaccines & Prevention and other partners, evaluated a series of preventive HIV vaccine regimens in uninfected human volunteers in five countries. In a similar study, Barouch and his colleagues tested the same vaccine for its ability to protect rhesus monkeys infected with a virus similar to HIV. The results showed that vaccines induce robust and comparable immune responses in humans and monkeys and monkeys protected against infection.
"This study demonstrates that the Ad26 / Ad26 mosaic vaccine candidate plus gp140 induces robust and comparable immune responses in humans and monkeys," said Barouch, who is also a professor of medicine at Harvard Medical School . "In addition, the vaccine provides 67% protection against viruses in monkeys."
Intended to provide broad protection against the many strains of HIV prevalent around the world, the "mosaic" vaccine contains a mosaic of genetic stem sequences. Known as the APPROACH, the Phase 1 / 2a trial tested seven Ad26 / Env vaccine regimens for safety, tolerability, and ability to elicit immune responses in 393 healthy adult volunteers in Rwanda. in South Africa, Thailand and the United States. Based on these data, the Ad26 / Env HIV-1 mosaic vaccine has been advanced in a Phase 2b clinical efficacy study to determine whether this vaccine will prevent HIV infection in humans in southern Africa, "said Barouch. "We are waiting for results in 2021. It is only the fifth concept of HIV vaccine that will be tested for efficacy in humans in the 35-year history of the epidemic. HIV. "
The study is the result of a collaboration between BIDMC researchers, Harvard Medical School and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard; the United States Military Research Program on HIV (MHRP) at the Walter Reed Army Research Institute (WRAIR); the National Institute of Allergy and Infectious Diseases (NIAID); the International AIDS Vaccine Initiative; the HIV Vaccine Trials Network (HVTN), Janssen Vaccines & Prevention B.V., part of Janssen Pharmaceutical Companies of Johnson & Johnson; and several other partners.
Source: Beth Israel Deaconess Medical Center
Source link
